Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission

Bone Marrow Transplantation volume 54, pages 1511–1514 (2019)Cite this article

Subjects

Outcomes in acute myeloid leukemia (AML) vary widely [1]. Current prognostic models cannot fully capture this diversity [2, 3], prompting interest in identifying additional factors to refine outcome prediction. Mounting evidence from other cancers suggests myeloid-derived suppressor cells (MDSCs) may be such a factor. Different types of MDSCs, including polymorphonuclear MDSCs (PMN-MDSCs; typically characterized as CD14 negative and CD11b, CD15, or CD66b positive) and monocytic MDSCs (M-MDSCs; typically characterized as CD14 positive and HLA-DR low/negative), have been studied as modulators of the anti-cancer immune response [4]. Expansion of MDSCs has been associated with poor prognosis in some solid tumors [5]. MDSCs may also play a role in the pathogenesis and/or prognosis of hematologic malignancies. For example, M-MDSCs expansion has been associated with poor outcome in myeloma [6] while MDSC signaling modulation can improve myelodysplastic hematopoiesis in vitro [7]. Less is known about the role(s) of MDSCs in AML. Not felt to be derived from the malignant clone, MDSCs are expanded in AML vs. healthy patients possibly because of leukemia–microenvironment interactions [8]. A small study also suggested that MDSC frequencies are associated with disease burden after AML chemotherapy [9] but larger studies on the prognostic role of MDSCs in AML are lacking. We hypothesized that in AML patients undergoing hematopoietic cell transplantation (HCT), leukemia burden pre-HCT would be associated with MDSC frequency and that elevated MDSC frequency could portend poor post-HCT outcomes in AML just as it portends poor prognosis in a variety of other malignancies [5,6,7]. Here, we used a large cohort of adults with AML (based on 2016 WHO criteria [10]) undergoing allogeneic HCT in first morphologic complete remission (CR) or CR with incomplete hematologic recovery (CRi) [1] to test this hypothesis and examine the associations between M-MDSC frequency, pre-transplant measurable (“minimal”) residual disease (MRD), and post-HCT outcome.

Adults ≥ 18 years of age were included if they underwent a first allograft after myeloablative or nonmyeloablative conditioning with peripheral blood or bone marrow (BM) as stem cell source from April 2006 until October 2014. We used the refined MRC/NCRI criteria to assign cytogenetic risk [11]. Secondary leukemia was defined as AML following an antecedent hematologic disorder or prior chemotherapy/radiotherapy treatment [12]. All patients were treated on Institutional Review Board (IRB)-approved protocols or standard treatment plans and gave consent in accordance with the Declaration of Helsinki. Follow-up was current as of 16 February 2018.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  Google Scholar 

  2. Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015;29:312–20.

    Article  CAS  Google Scholar 

  3. Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW, et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia. 2015;29:2104–7.

    Article  CAS  Google Scholar 

  4. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.

    Article  CAS  Google Scholar 

  5. Toor SM, Elkord E. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer. Immunol Cell Biol. 2018;96:888–97.

    Article  Google Scholar 

  6. Wang Z, Zhang L, Wang H, Xiong S, Li Y, Tao Q, et al. Tumor-induced CD14 + HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. Cancer Immunol Immunother. 2015;64:389–99.

    Article  CAS  Google Scholar 

  7. Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31:2172–80.

    Article  CAS  Google Scholar 

  8. Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, et al. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017;129:1791–801.

    Article  CAS  Google Scholar 

  9. Sun H, Li Y, Zhang ZF, Ju Y, Li L, Zhang BC, et al. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol. 2015;102:579–86.

    Article  CAS  Google Scholar 

  10. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  CAS  Google Scholar 

  11. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.

    Article  CAS  Google Scholar 

  12. Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29:137–44.

    Article  CAS  Google Scholar 

  13. Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:1190–7.

    Article  Google Scholar 

  14. Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329–36.

    Article  Google Scholar 

  15. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE. 2014;9:e87705.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by grants P01-CA078902, P01-CA018029, and P30-CA015704 from the National Cancer Institute/National Institutes of Health (NCI/NIH) and a fellowship training grant from the National Heart, Lung, and Blood Institute (NHLBI)/NIH (T32-HL007093, to C.D.G.). R.B.W. is a Leukemia & Lymphoma Society Scholar in Clinical Research.

Author information

Authors and Affiliations

  1. Hematology/Oncology Fellowship Program, University of Washington, Seattle, WA, USA

    Colin D. Godwin

  2. Department of Laboratory Medicine, Division of Hematopathology, University of Washington, Seattle, WA, USA

    Jonathan R. Fromm & Brent L. Wood

  3. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Megan Othus

  4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Brenda M. Sandmaier, Marco B. Mielcarek, Frederick R. Appelbaum, Rainer Storb & Roland B. Walter

  5. Department of Medicine, University of Washington, Seattle, WA, USA

    Brenda M. Sandmaier, Marco B. Mielcarek, Frederick R. Appelbaum, Rainer Storb & Roland B. Walter

  6. Department of Epidemiology, University of Washington, Seattle, WA, USA

    Roland B. Walter

  7. Department of Pathology, University of Washington, Seattle, WA, USA

    Roland B. Walter

Authors
  1. Colin D. Godwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan R. Fromm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Megan Othus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brenda M. Sandmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marco B. Mielcarek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brent L. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Frederick R. Appelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rainer Storb
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Roland B. Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

C.D.G., J.R.F, and R.B.W. contributed to the study design and wrote the manuscript; C.D.G and J.R.F. collected and analyzed data; M.O. and R.B.W. performed statistical analyses; B.M.S., M.B.M., B.L.W, F.R.A., and R.S. collected and provided patient data and edited the manuscript. All authors read and agreed on the final version of the manuscript.

Corresponding author

Correspondence to Colin D. Godwin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflit of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Godwin, C.D., Fromm, J.R., Othus, M. et al. Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. Bone Marrow Transplant 54, 1511–1514 (2019). https://doi.org/10.1038/s41409-019-0481-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0481-9

Search

Advanced search

Quick links